1-20 of 190 results for subject:Rubella
Librarians' tools
- Search time
- 0.367 seconds
- Solr query time
- 0.004 seconds
- Search query
- subject:Rubella
- We searched for
- subject_t:Rubella OR subject_t:"German measles" OR subject_ses:10437
Type
House
Session
Year
Department
Member
More
Primary member
More
Answering member
More
Legislative stage
Legislation
Subject
More
Publisher
To ask His Majesty's Government how many cases of (1) measles, (2) whooping cough, (3) mumps, (4) rubella, and (5) polio, were recorded in each of the last three years.
To ask His Majesty's Government how many cases of (1) measles, (2) whooping cough, (3) mumps, (4) rubella, and (5) polio, were recorded in each of the last three years.
The following table shows the UK Health Security Agency’s (UKHSA) routinely published data on laboratory confirmed cases of measles, mumps, rubella, and pertussis, also known as whooping cough, in 2022, 2023, and 2024:
Disease | 2024 | 2023 | 2022 |
Measles | 2,911 | 367 | 53 |
Mumps | 137 | 161 | 59 |
Rubella | 0 | 0 | 0 |
Pertussis | 14,894 | 856 | 68 |
The United Kingdom was declared polio-free by the World Health Organization in 2003. The last case of natural polio infection acquired in the UK was in 1984.
To ask the Secretary of State for Health and Social Care, what recent estimate he has made of the number of people who are infected with Measles, Mumps and Rubella.
To ask the Secretary of State for Health and Social Care, what recent estimate he has made of the number of people who are infected with Measles, Mumps and Rubella.
In England, there were two laboratory confirmed cases of measles and seven mumps infections reported in 2021. No new laboratory confirmed cases of rubella have been reported in the United Kingdom since 2019.
This House of Lords Library Briefing focuses on the measles, mumps and rubella (MMR) jab. It looks at social media’s role in the spread of misinformation, what the UK Government and social media companies have pledged to do about it, and what other countries are doing to solve declining rates of MMR vaccination.
This House of Lords Library Briefing focuses on the measles, mumps and rubella (MMR) jab. It looks at social media’s role in the spread of misinformation, what the UK Government and social media companies have pledged to do about it, and what other countries are doing to solve declining rates...
This House of Lords Library Briefing Pack contains a selection of material relevant for the forthcoming question for short debate on what plans Her Majesty’s Government have to promote the uptake of vaccinations and health screening services.
This House of Lords Library Briefing Pack contains a selection of material relevant for the forthcoming question for short debate on what plans Her Majesty’s Government have to promote the uptake of vaccinations and health screening services.
My hon. Friend raises an important point. The UK is the largest donor to GAVI, the Vaccine Alliance, which protects children from rubella through measles and rubella vaccinations, and of course GAVI has been set up very much to do exactly what my hon. Friend says. We have the UK aid match scheme, and Sense International has received over £200,000 for this very purpose in Uganda and Kenya in particular. I look forward to hearing from my hon. Friend about his findings from his visit.
My hon. Friend raises an important point. The UK is the largest donor to GAVI, the Vaccine Alliance, which protects children from rubella through measles and rubella vaccinations, and of course GAVI has been set up very much to do exactly what my hon. Friend says. We have the UK aid match scheme, and Sense International has received over £200,000 for this very purpose in Uganda and Kenya in particular. I look forward to hearing from my hon. Friend about his findings from his visit.
I recently visited Uganda and was proud to see British taxpayers’ money being used to vaccinate children against all sorts of diseases, but rubella is one area where we are failing to help. Please can my right hon. Friend look at ways in which we could use international development aid to vaccinate children against this hideous condition?
I recently visited Uganda and was proud to see British taxpayers’ money being used to vaccinate children against all sorts of diseases, but rubella is one area where we are failing to help. Please can my right hon. Friend look at ways in which we could use international development aid to vaccinate children against this hideous condition?
I recently visited Uganda and was proud to see British taxpayers’ money being used to vaccinate children against all sorts of diseases, but rubella is one area where we are failing to help. Please can my right hon. Friend look at ways in which we could use international development aid to vaccinate children against this hideous condition?
My hon. Friend raises an important point. The UK is the largest donor to GAVI, the Vaccine Alliance, which protects children from rubella through measles and rubella vaccinations, and of course GAVI has been set up very much to do exactly what my hon. Friend says. We have the UK aid match scheme, and Sense International has received over £200,000 for this very purpose in Uganda and Kenya in particular. I look forward to hearing from my hon. Friend about his findings from his visit.
To ask the Secretary of State for International Development, what steps her Department has taken to help tackle rubella in Africa.
To ask the Secretary of State for International Development, what steps her Department has taken to help tackle rubella in Africa.
Rubella is a vaccine-preventable disease. The UK is the largest donor to Gavi, the Vaccine Alliance, which protects children from rubella through the Measles-Rubella vaccine. By the end of 2015, Gavi had immunised 164 million children with measles-rubella vaccine.
From 2016 to 2020 Gavi will greatly scale up the Measles-Rubella vaccine, averting more than 1 million future deaths, and greatly reducing the number of children in Africa who suffer from Congenital Rubella Syndrome each year. In total, the UK will invest £1.44bn in Gavi between 2016 and 2020, to immunise 76 million children and save 1.4 million lives.
The Department for International Development supports countries to strengthen their health care systems so that they can provide good quality services to prevent and treat all the main illnesses affecting children, including Congenital Rubella Syndrome.
To ask the Secretary of State for International Development, what steps her Department has taken to help tackle rubella contracted by children in Africa.
To ask the Secretary of State for International Development, what steps her Department has taken to help tackle rubella contracted by children in Africa.
Rubella is a vaccine-preventable disease. The UK is the largest donor to Gavi, the Vaccine Alliance, which protects children from rubella through the Measles-Rubella vaccine. By the end of 2015, Gavi had immunised 164 million children with measles-rubella vaccine.
From 2016 to 2020 Gavi will greatly scale up the Measles-Rubella vaccine, averting more than 1 million future deaths, and greatly reducing the number of children in Africa who suffer from Congenital Rubella Syndrome each year. In total, the UK will invest £1.44bn in Gavi between 2016 and 2020, to immunise 76 million children and save 1.4 million lives.
The Department for International Development supports countries to strengthen their health care systems so that they can provide good quality services to prevent and treat all the main illnesses affecting children, including Congenital Rubella Syndrome.
asked Her Majesty's Government:How many adverse reactions to measles, mumps and rubella vaccines have been reported by parents and medical professionals since their introduction; and how many of those reported adverse reactions included bowel problems.
asked Her Majesty's Government:How many adverse reactions to measles, mumps and rubella vaccines have been reported by parents and medical professionals since their introduction; and how many of those reported adverse reactions included bowel problems.
| Reaction Term (PT) | Number of suspected ADR reports received |
| Anal Inflammation | 1 |
| Colitis | 1 |
| Colitis Ulcerative | 2 |
| Crohn's Disease | 9 |
| Enteritis | 3 |
| Inflammatory Bowel Disease | 4 |
| Total: | 20 |
What is the unit cost of a single dose of measles, mumps and rubella (MMR) vaccine; and what are the unit costs of each of the MMR vaccine constituents if given as separate doses.
What is the unit cost of a single dose of measles, mumps and rubella (MMR) vaccine; and what are the unit costs of each of the MMR vaccine constituents if given as separate doses.
To ask the Secretary of State for Health how many children in (a) Southend, (b) Essex and (c) Hertfordshire have been given (i) the single MMR vaccine and (ii) the three separate vaccines in each of the last five years for which figures are available.
To ask the Secretary of State for Health how many children in (a) Southend, (b) Essex and (c) Hertfordshire have been given (i) the single MMR vaccine and (ii) the three separate vaccines in each of the last five years for which figures are available.
| Percentage | |||
|---|---|---|---|
| Southend | Essex | Hertfordshire | |
| 2000–01 | n/a | 89 | 90 |
| 2001–02 | n/a | 85 | 84 |
| 2002–03 | 79 | 81 | 83 |
| 2003–04 | 73 | 77 | 79 |
| 2004–05 | 74 | 78 | 81 |
| n/a = not available Source: COVER—data collection system (regulated by Department of Health) |
To ask the Secretary of State for Health from which countries United Kingdom registered companies that provide MMR vaccines to the NHS source their products.
To ask the Secretary of State for Health from which countries United Kingdom registered companies that provide MMR vaccines to the NHS source their products.
Whether manufacturers of single measles, mumps and rubella vaccines have been instructed not to market their vaccines within the United Kingdom; whether they will have their licences withdrawn if they are found to have done so; and, if so, what were the reasons for the instruction. [HL 493].
Whether manufacturers of single measles, mumps and rubella vaccines have been instructed not to market their vaccines within the United Kingdom; whether they will have their licences withdrawn if they are found to have done so; and, if so, what were the reasons for the instruction. [HL 493].
Lords debate on unstarred question on what Her Majesty's Government propose to do to increase the level of public trust in their vaccination and immunisation programme.
Lords debate on unstarred question on what Her Majesty's Government propose to do to increase the level of public trust in their vaccination and immunisation programme.
Vaccines and public health, June 2004. POSTnote 04/219.
Vaccines and public health, June 2004. POSTnote 04/219.
To ask the Secretary of State for Health, what his policy is on ensuring that there is an adequate provision of serum for children whose parents opt for individual inoculations rather than the combined MMR.
To ask the Secretary of State for Health, what his policy is on ensuring that there is an adequate provision of serum for children whose parents opt for individual inoculations rather than the combined MMR.
To ask the Secretary of State for Health, whether there is a shortage of serum for (a) measles, (b) mumps and (c) rubella for children whose parents opt for individual inoculations; and if he will make a statement. - Department holds no information about the supply of single vaccines.
To ask the Secretary of State for Health, whether there is a shortage of serum for (a) measles, (b) mumps and (c) rubella for children whose parents opt for individual inoculations; and if he will make a statement. - Department holds no information about the supply of single vaccines.
Adjournment debate on MMR vaccinations and autism.
Adjournment debate on MMR vaccinations and autism.
To ask the Secretary of State for Health, how many children aged between 5 and 15 years developed (a) measles, (b) mumps and (c) rubella in each of the last 10 years. - Inc table from 1995.
To ask the Secretary of State for Health, how many children aged between 5 and 15 years developed (a) measles, (b) mumps and (c) rubella in each of the last 10 years. - Inc table from 1995.
Whether the research currently being conducted by the Moyne Institute of Preventive Medicine in Dublin into developing a vaccine to combat measles, mumps and rubella relying on recombinant ribonucleic acid instead of live viruses holds out the prospect of fewer adverse reactions; and whether they will monitor the results of...
Whether the research currently being conducted by the Moyne Institute of Preventive Medicine in Dublin into developing a vaccine to combat measles, mumps and rubella relying on recombinant ribonucleic acid instead of live viruses holds out the prospect of fewer adverse reactions; and whether they will monitor the results of...